Adamas Pharma (ADMS) Tops Q2 EPS by 2c

Adamas Pharma (NASDAQ: ADMS) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $22 million versus the consensus estimate of $21.95 million.

Full year 2021 expense guidance:

For full year 2021, Adamas is reiterating its estimates for R&D, SG&A and stock-based compensation expenses as set forth below:

1Includes stock-based compensation expense of $1 million.
2Includes stock-based compensation expense of $8 million.
3Includes stock-based compensation expense of $9 million.

For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Reading (RDI) Tops Q2 EPS by 4c